Skip to content

Depression: all studies

Page 701 of 1,034: studies 7,001 to 7,010 of 10,336, newest first. Back to the depression overview

Research

Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS.

Scientific Reports July 19, 2023 Adelaida Castillo, Julien Dubois, Ryan M. Field et al. 19 citations

Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind,...

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings

Frontiers in Human Neuroscience July 18, 2023 Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra et al. 29 citations

Background Psychedelic drug experiences are shaped by current-moment contextual factors, commonly categorized as internal (set) and external (setting). Potential influences of past environments, however, have received little attention. Aims To investigate how previous environmental stimuli shaped the experiences of patients receiving ketamine for treatment-resistant depression (TRD), and...

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Response to Letter].

Neuropsychiatric Disease and Treatment July 17, 2023 Cheng-Chuan Chen, Xiao-Bin Wang

Thank you very much for your attention and advice, as this is indeed a thought-provoking issue. Although the US Food and Drug Administration (FDA) has not yet recognized the advantages of ketamine in treating depression and preventing suicide, relevant research results show that ketamine also has a significant role in preventing suicide. In contrast, as the only drug approved by the FDA,...

Mediators of change in online mindfulness-based cognitive therapy: A secondary analysis of a randomized trial of mindful mood balance.

Journal of Consulting and Clinical Psychology July 17, 2023 Sona Dimidjian, Robert Gallop, Joseph J. Lévy et al. 14 citations

OBJECTIVE: Digital delivery of mindfulness-based cognitive therapy through the Mindful Mood Balance (MMB) program is clinically effective (Segal et al., 2020); however, the mechanisms through which this program delivers its benefits have not been established. METHOD: This study investigates the differential impact of the MMB program paired with usual depression care (UDC) compared to UDC alone...

Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking

Pharmaceuticals July 17, 2023 Glorister A. Altê, Ana Lúcia S Rodrigues 17 citations

Ketamine, a racemic mixture of esketamine (S-ketamine) and arketamine (R-ketamine), has received particular attention for its rapid antidepressant and antisuicidal effects. NMDA receptor inhibition has been indicated as one of the main mechanisms of action of the racemic mixture, but other pharmacological targets have also been proposed. This study aimed to explore the possible multiple targets...

DOI: 10.3390/ph16071013 (opens in new tab) Ketamine Kegg Antidepressant Computational biology +7

Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study).

The Journal of Headache and Pain July 14, 2023 Licia Grazzi, Domenico D'Amico, Erika Guastafierro et al.

Mindfulness gained considerable attention for migraine management, but RCTs are lacking. We aimed to assess the efficacy of a six-sessions mindfulness-based treatment added to treatment as usual (TaU) in patients with Chronic Migraine (CM) and Medication Overuse Headache (MOH) on headache frequency, medication intake, quality of life, disability, depression and anxiety, cutaneous allodynia,...

Exploring the Therapeutic Potential of DMT as an Antipsychotic: A Comprehensive Review

European Chemical Bulletin July 13, 2023 Lalit Singh preprint

This review article explores the potential of N,N-Dimethyltryptamine (DMT) as an antipsychotic drug, acknowledging its therapeutic potential while addressing the controversies and potential risks associated with its use. DMT has distinctive effects on fast brain plasticity and functions as a serotonin agonist hallucinogen, primarily at the 5-HT2A receptor, immune-modulation, and in influencing...

Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review

Advances in Mental Health July 13, 2023 Jorge Valdiviezo‐oña, Lizbeth Toscano-Molina, Juan Fernando Chávez et al. 4 citations

Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) and their outcomes.Method To be included, peer-reviewed articles had to be written in English or Spanish and had to address the usage of psychedelics by people reporting an ED. Searches were conducted on PubMed, Scopus, and Web of Science. Data on key...

Mindfulness supports emotional resilience in children during the COVID-19 pandemic

PLoS One July 12, 2023 Isaac N Treves, Cindy E Li, Kimberly L. Wang et al. 18 citations

An important aspect of mental health in children is emotional resilience: the capacity to adapt to, and recover from, stressors and emotional challenges. Variation in trait mindfulness, one's disposition to attend to experiences with an open and nonjudgmental attitude, may be an important individual difference in children that supports emotional resilience. In this study, we investigated...